[1]杨成会,缪珩.二甲双胍在甲状腺疾病治疗中的作用[J].国际内分泌代谢杂志,2015,(04):255-257,263.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
　Yang Chenghui,Miao Heng..Roles of metformin in the treatment of thyroid diseases[J].International Journal of Endocrinology and Metabolism,2015,(04):255-257,263.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
点击复制

二甲双胍在甲状腺疾病治疗中的作用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2015年04
页码:
255-257,263
栏目:
甲状腺疾病专栏
出版日期:
2015-07-20

文章信息/Info

Title:
Roles of metformin in the treatment of thyroid diseases
作者:
杨成会; 缪珩
210000　南京医科大学第二附属医院内分泌科
Author(s):
Yang Chenghui; Miao Heng.
Department of Endocrinology，The Second Affiliated Hospital of Nanjing Medical University，Nanjing 210000，China Corresponding author：Miao Heng，Email：miaoheng@medmail.com.cn
关键词:
二甲双胍; 促甲状腺激素; 甲状腺结节; 甲状腺癌
Keywords:
Metformin; Thyrotropin; Thyroid nodule; Thyroid cancer
DOI:
10.3760/cma.j.issn.1673-4157.2015.04.011
摘要:
二甲双胍是治疗糖尿病较为安全、有效的一线药物之一。近年来，有研究报道糖尿病患者常伴有甲状腺功能减退症及甲状腺结节增生，其甲状腺癌的发病率也明显增加。而服用二甲双胍可以改善胰岛素抵抗、减轻高胰岛素血症，降低促甲状腺激素（TSH）水平，减少甲状腺结节的增生，并阻滞细胞周期进程，抑制甲状腺癌细胞的增殖，协同增强化学治疗药物的敏感性。因此，二甲双胍有可能在辅助治疗甲状腺疾病中发挥重要角色。
Abstract:
Metformin，the first-line medicine for the treatment of diabetes，is generally considered to be a relatively safe and effective drug. In recent years，some studies have reported that diabetic patients are often accompanied by hypothyroidism，thyroid nodular hyperplasia，and the rising incidence of thyroid cancer， while taking metformin can improve insulin resistance，reduce hyperinsulinemia，decrease thyroid stimulating hormone （TSH） levels，suppress the hyperplasia of thyroid nodules，block the cell cycle progression and inhibit the proliferation of thyroid cancer cells，as well as synergistically enhance the sensitivity to chemotherapeutic drugs. Therefore，metformin may play an important role in the adjuvant treatment of thyroid diseases.

参考文献/References:

[1]　Distiller LA，Polakow ES，Joffe BI.Type 2 diabetes mellitus and hypothyroidism：the possible influence of metformin therapy[J].Diabet Med，2014，31（2）：172-175. 　
[2]　Palma CC，Pavesi M，Nogueira VG，et al.Prevalence of thyroid dysfunction in patients with diabetes mellitus[J].Diabetol Metab Syndr，2013，5（1）：58. 　
[3]　Al-Geffari M，Ahmad NA，Al-Sharqawi AH，et al.Risk factors for thyroid dysfunction among type 2 diabetic patients in a highly diabetes mellitus prevalent society[J].Int J Endocrinol，2013， 2013：417920. 　
[4]　Díez JJ，Iglesias P.An analysis of the relative risk for hypothy-roidism in patients with type 2 diabetes[J].Diabet Med，2012， 29（12）：1510-1514. 　
[5]　Joffe BI，Distiller LA.Diabetes mellitus and hypothyroidism： strange bedfellows or mutual companions?[J].World J Diabetes，2014，5（6）：901-904. 　
[6]　张宏，赵伟，朱梦瑜，等.糖尿病大鼠甲状腺组织TG，TPO， TSHR与RAGE mRNA表达的实验研究[J].国际内分泌代谢杂志，2009，29（4）：240-243. 　
[7]　Cappelli C，Rotondi M，Pirola I，et al.TSH-lowering effect of metformin in type 2 diabetic patients：differences between euthyroid， untreated hypothyroid，and euthyroid on L-T4 therapy patients[J].Diabetes Care，2009，32（9）：1589-1590. 　
[8]　Cappelli C，Rotondi M，Pirola I，et al.Thyreotropin levels in diabetic patients on metformin treatment[J].Eur J Endocrinol，2012，167（2）：261-265. 　
[9]　Díez JJ，Iglesias P.Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes[J].Clin Endocrinol（Oxf），2013，78（4）：505-511.
[10]　Fournier JP，Yin H，Yu OH，et al.Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus[J]. CMAJ，2014，186（15）：1138-1145.
[11]　Lupoli R，Di Minno A，Tortora A，et al.Effects of treatment with metformin on TSH levels：a meta-analysis of literature studies[J].J Clin Endocrinol Metab，2013，99（1）：E143-E148.
[12]　Krysiak R，Okopien B.Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone[J].Clin Endocrinol（Oxf），2011，75（3）：404-406.
[13]　Cappelli C，Rotondi M，Pirola I，et al.Metformin-induced thyrotropin suppression is not associated with cardiac effects[J].Hormones （Athens），2014，13（2）：252-258.
[14]　Hausman GJ，Barb CR，Lents CA.Leptin and reproductive function [J].Biochimie，2012，94（10）：2075-2081.
[15]　Pazaitou-Panayiotou K，Polyzos SA，Mantzoros CS.Obesity and thyroid cancer：epidemiologic associations and underlying mech-anisms[J]. Obes Rev，2013，14（12）：1006-1022.
[16]　Anil C，Akkurt A，Ayturk S，et al.Impaired glucose metabolism is a risk factor for increased thyroid volume and nodule prevalence in a mild-to-moderate iodine deficient area[J].Metabolism，2013，62（7）：970-975.
[17]　Blanc E，Ponce C，Brodschi D，et al.Association between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome[J].Metab Syndr Relat Disord，2015，13（5）：221-226.
[18]　Yasar HY，Ertu?觧rul ?魻，Ertu?觧rul B，et al.Insulin resistance in nodular thyroid disease[J].Endocr Res，2011，36（4）：167-174.
[19]　Rezzónico J，Rezzónico M，Pusiol E，et al.Metformin treatment for small benign thyroid nodules in patients with insulin resistance[J]. Metab Syndr Relat Disord，2011，9（1）：69-75.
[20]　Ittermann T，Markus MR，Schipf S，et al.Metformin inhibits goitrogenous effects of type 2 diabetes[J].Eur J Endocrinol，2013， 169（1）：9-15.
[21]　Andrade BM，Araujo RL，Perry RL，et al.A novel role for AMP-kinase in the regulation of the Na+/I- symporter and iodide up-take in the rat thyroid gland[J].Am J Physiol Cell Physiol，2011， 300（6）： C1291-C1297.
[22]　Duran AO，Anil C，Gursoy A，et al.The relationship between glucose metabolism disorders and malignant thyroid disease[J].Int J Clin Oncol，2013，18（4）：585-589.
[23]　Schmidt JA，Allen NE，Almquist M，et al.Insulin-like growth factor-i and risk of differenttiated thyroid carcinoma in the European prospective investigation into cancer and nutrition[J].Cancer Epidemiol Biomarkers Prev，2014，23（6）：976-985.
[24]　Currie CJ，Poole CD，Gale EA.The influence of glucose-lowering therapies on cancer risk in type 2 diabetes[J].Diabetologia，2009，52（9）：1766-1777.
[25]　Ioacara S，Guja C，Ionescu-Tirgoviste C，et al.Cancer specific mortality in insulin-treated type 2 diabetes patients[J].PLoS One， 2014，9（3）：e93132.
[26]　Cho SW，Yi KH，Han SK，et al.Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo[J].Mol Cell Endocrinol，2014，393（1-2）：24-29.
[27]　Klubo-Gwiezdzinska J，Jensen K，Costello J，et al.Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells[J].Endocr Relat Cancer，2012，19（3）：447-456.
[28]　Klubo-Gwiezdzinska J，Costello J Jr，Patel A，et al.Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer[J].J Clin Endocrinol Metab， 2013，98（8）：3269-3279.
[29]　Chen G，Xu S，Renko K，et al.Metformin inhibits growth of thyroid carcinoma cells，suppresses self-renewal of derived cancer stem cells， and potentiates the effect of chemotherapeutic agents[J].J Clin Endocrinol Metab，2012，97（4）：E510-E520.
[30]　Rotondi M，Coperchini F，Pignatti P，et al.Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells：an additional indirect anti-tumor effect of the drug[J].J Clin Endocrinol Metab，2015，100（3）：E427-E432.

相似文献/References:

[1]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[2]尹飞,李菲,李志红.亚临床甲状腺功能异常与骨质疏松[J].国际内分泌代谢杂志,2015,(04):258.[doi:10.3760/cma.j.issn.1673-4157.2015.04.012]
　Yin Fei,Li Fei,Li Zhihong..Subclinical thyroid dysfunction and osteoporosis[J].International Journal of Endocrinology and Metabolism,2015,(04):258.[doi:10.3760/cma.j.issn.1673-4157.2015.04.012]
[3]杨健姝,华飞,唐暎,等.二甲双胍在多囊卵巢综合征患者妊娠期的应用[J].国际内分泌代谢杂志,2014,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2014.03.009]
　Yang Jianshu,Hua Fei,Tang Ying,et al.The application of metformin in the pregnant patients with polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2014,(04):176.[doi:10.3760/cma.j.issn.1673-4157.2014.03.009]
[4]何玮婧,陈立勇,赵家军.促甲状腺激素与肥胖[J].国际内分泌代谢杂志,2014,(04):260.[doi:10.3760/cma.j.issn.1673-4157.2014.04.013]
　He Weijing,Chen Liyong,Zhao Jiajun..Thyroid stimulating hormone and obesity[J].International Journal of Endocrinology and Metabolism,2014,(04):260.[doi:10.3760/cma.j.issn.1673-4157.2014.04.013]
[5]翟丽敏,叶山东.二甲双胍的抗炎作用及其糖尿病肾脏保护作用[J].国际内分泌代谢杂志,2014,(05):334.[doi:10.3760/cma.j.issn.1673-4157.2014.05.013]
　Zhai Limin,Ye Shandong..Anti-inflammatory effects of metformin and its renal protection in diabetes[J].International Journal of Endocrinology and Metabolism,2014,(04):334.[doi:10.3760/cma.j.issn.1673-4157.2014.05.013]
[6]李尤佳,关海霞.促甲状腺激素参考范围的影响因素[J].国际内分泌代谢杂志,2017,37(02):90.[doi:10.3760/cma.j.issn.1673-4157.2017.02.005]
　Li Youjia,Guan Haixia..The influence factors of serum thyrotropin reference range[J].International Journal of Endocrinology and Metabolism,2017,37(04):90.[doi:10.3760/cma.j.issn.1673-4157.2017.02.005]
[7]孟祥慧 徐书杭 陈国芳 刘超.二甲双胍在甲状腺癌防治中的作用[J].国际内分泌代谢杂志,2018,38(04):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
　Meng Xianghui*,Xu Shuhang,Chen Guofang,et al.Role of metformin in prevention and treatment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2018,38(04):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
[8]林杨 叶山东.二甲双胍对糖尿病肾病保护作用的机制[J].国际内分泌代谢杂志,2018,38(01):52.[doi:10.3760/cma.j.issn.1673-4157.2018.01.014]
　Lin Yang*,Ye Shandong. *.Protective effects of metformin on diabetic nephropathy and its mechanism[J].International Journal of Endocrinology and Metabolism,2018,38(04):52.[doi:10.3760/cma.j.issn.1673-4157.2018.01.014]
[9]李静,李曙光,乐岭.二甲双胍抑制分化型甲状腺癌的作用及机制[J].国际内分泌代谢杂志,2021,41(01):28.[doi:10.3760/cma.j.cn121383-20200514-05032]
　Li Jing,Li Shuguang,Yue Ling..Effects and mechanisms of metformin on differentiated thyroid cancer[J].International Journal of Endocrinology and Metabolism,2021,41(04):28.[doi:10.3760/cma.j.cn121383-20200514-05032]
[10]王慧,李忠淑.二甲双胍联合恩替卡韦治疗2型糖尿病合并HBV感染并发NAFLD的疗效分析[J].国际内分泌代谢杂志,2022,42(02):124.[doi:10.3760/cma.j.cn121383-20200711-07031]
　Wang Hui,Li Zhongshu..Therapeutic effect of metformin combined with entecavir on type 2 diabetes mellitus complicated with HBV infection and NAFLD[J].International Journal of Endocrinology and Metabolism,2022,42(04):124.[doi:10.3760/cma.j.cn121383-20200711-07031]

备注/Memo

备注/Memo:
通信作者：缪珩，Email：miaoheng@medmail.com.cn
更新日期/Last Update: 2015-07-20